New Data Show Many Rheumatoid Arthritis Patients Treated With ENBREL Plus Methotrexate Have Experienced Clinical Remission and Most Had No Progression of Joint Damage
Additional ENBREL Five-Year Data Support Long-term
Efficacy and Tolerability in Rheumatoid Arthritis
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Oct. 24 --
More than one third (37 percent) of rheumatoid arthritis (RA) patients treated
with Enbrel(R) (etanercept) plus methotrexate combination therapy achieved
clinical remission of their disease at one year as measured by the Disease
Activity Score (DAS) criteria. In addition, 80 percent of combination-treated
patients experienced no progression of joint damage and a majority
(51 percent) of patients reported significant improvement in functionality at
one year. Results from the ENBREL TEMPO, (Trial of Etanercept and
Methotrexate with Radiographic Patient Outcomes) study were presented at the
American College of Rheumatology's (ACR) Annual Scientific Meeting in Orlando,
"It is very exciting as a physician to see such a sizeable proportion of
combination therapy RA patients in this study achieve clinical remission and,
for the first time, statistically significant, credible evidence of negative
progression scores," said Desiree van der Heijde, M.D., professor of
rheumatology, University of Maastricht in the Netherlands. "The outstanding
results of the ENBREL TEMPO study underscore the importance of aggressive
treatment of RA and give new insight to combination treatment of the disease."
At one year, 37 percent of patients taking combination therapy of ENBREL
and methotrexate (n=212) achieved clinical remission, as assessed by the
Disease Activity Score (DAS). In comparison, 18 percent of patients treated
with ENBREL alone (n=212) and 14 percent of patients treated with methotrexate
alone (n=212) achieved clinical remission during the same time period.
Clinical remission is defined as a DAS score of <1.6. DAS scores measure
tender and swollen joints, erythrocyte sedimentation rate (ESR), an
inflammatory marker found in the blood, and overall disease activity.
"This is the first time any TNF inhibitor in combination with methotrexate
has demonstrated the ability to help this many patients achieve clinical
remission as measured by DAS criteria-a major goal of RA therapy," said
Willard Dere, M.D., vice president of clinical development for Amgen.
Additionally, 80 percent of combination-treated patients experienced no
progression of joint damage (unit change of TSS<0.5) at one year as assessed
by the van der Heijde modified Total Sharp Score (TSS), an x-ray measurement
of changes in joint damage. In comparison, 68 percent and 57 percent of
ENBREL monotherapy and methotrexate monotherapy-treated patients,
respectively, had no progression of joint damage at one year. Combination
therapy patients also achieved a mean negative Total Sharp Score (-0.5 unit
mean change, 95 percent confidence interval of -1.00 to -0.07). ENBREL
monotherapy patients experienced significantly less progression of joint
damage compared with methotrexate monotherapy patients, with a 0.5 unit mean
change from baseline at one year in TSS compared with a 2.8 unit mean change.
At one year, a substantial percentage of patients experienced an
improvement in RA symptoms. In the ENBREL and methotrexate combination group,
85 percent of patients achieved ACR 20, 69 percent achieved ACR 50 and
43 percent of patients achieved ACR 70. ACR scores are a composite measure of
improvement in RA symptoms, including joint swelling and tenderness, pain,
level of disability, overall self and physician assessment, and an objective
marker of inflammation, such as ESR.
Patients also completed a Health Assessment Questionnaire (HAQ), which
measures functionality. Fifty-one percent of combination therapy patients
reported an improvement in HAQ scores of greater than or equal to 1,
indicating a significant improvement in functionality.
The ENBREL TEMPO study randomized 682 patients with RA, of which 642 were
included in radiographic analysis for a period of one year to receive ENBREL
(25 mg twice weekly), methotrexate (up to 20 mg once weekly) or ENBREL
(25 mg twice weekly) plus methotrexate twice weekly. Patients in the ENBREL
TEMPO trial had active RA and an inadequate response to at least one
disease-modifying antirheumatic drug (DMARD) other than methotrexate. The
primary radiographic endpoint was the change from baseline in van der
Heijde-modified TSS at one year. Secondary radiographic endpoints included
the changes in total erosions, changes in total joint space narrowing, number
of eroded joints and non-progression (TSS change less than or equal to 0.5 or
TSS change less than or equal to 3.0 or progression greater than the smallest
Proven Efficacy and Tolerability Over a Five-Year Period
Results from a long-term follow up study of patients enrolled in the
original ENBREL studies, some of which lead to FDA approval of ENBREL five
years ago, further support the continued efficacy and tolerability of ENBREL.
This study followed more than 2,000 patients taking ENBREL. A subset of these
patients was followed for as long as five years. Thirty percent of those
patients experienced no tender joints, 23 percent had no swollen joints and
16 percent had a Health Assessment Questionnaire (HAQ) score of zero, which
indicates no disability, at the five-year mark (n=329). Additionally, the
rate of infections was comparable to that of control groups in controlled
"ENBREL has been enhancing the lives of individuals with RA for more than
five years, reducing disability and helping them to return to more normal
lives," says Victoria Kusiak, M.D., vice president of global medical affairs
and North American medical director of Wyeth Pharmaceuticals. "These data
reinforce the proven tolerability and sustained efficacy of ENBREL in patients
with RA, and we are committed to exploring its use to help patients across a
number of TNF-activated disorders."
More than two million Americans suffer from RA, which causes stiffness,
swelling and limitation in the motion and function of multiple joints. If
left untreated, or improperly treated, patients can become disabled from
irreversible joint damage caused by the disease, limiting their ability to
ENBREL is the only fully human TNF receptor approved to reduce signs and
symptoms, improve physical function, and inhibit the progression of structural
damage in patients with moderately to severely active rheumatoid arthritis
(RA), and to reduce the signs and symptoms and inhibit the progression of
structural damage of active arthritis in patients with psoriatic arthritis.
ENBREL is the only biologic therapy approved for first-line treatment of RA
patients, and can be used alone or in combination with methotrexate. It is
approved to reduce the signs and symptoms of moderately to severely active
polyarticular-course juvenile rheumatoid arthritis (JRA) in patients who have
had an inadequate response to one or more disease-modifying antirheumatic
drugs (DMARDs). It is also the first biologic approved to treat the signs and
symptoms in patients with active ankylosing spondylitis (AS).
ENBREL has been used by more than 200,000 patients worldwide across
indications since becoming commercially available nearly five years ago.
ENBREL acts by binding TNF, one of the dominant inflammatory cytokines or
regulatory proteins that play an important role in both normal immune function
and the cascade of reactions that causes the inflammatory process of RA, JRA,
psoriatic arthritis and AS. The binding of ENBREL to TNF renders the bound
TNF biologically inactive, resulting in significant reduction in inflammatory
Since the product was first introduced, the following have been reported
in patients using ENBREL:
* Serious Infections
- Many occurred in people prone to infection, such as those with
advanced or poorly controlled diabetes
- Some serious infections were fatal
- Rare cases of tuberculosis
* What to do/Not do
- Do not start ENBREL if you have an infection or are allergic to
ENBREL or its components
- Tell your doctor if you are prone to infection
- Stop ENBREL if a serious infection occurs
- Contact your doctor if you have questions about ENBREL or develop
* Serious nervous system disorders such as multiple sclerosis, seizures,
or inflammation of the nerves of the eyes.
- Tell your doctor if you have ever had any of these disorders or if
you develop them after starting ENBREL.
* Rare reports of serious blood disorders (some fatal)
- Contact your doctor immediately if you develop symptoms such as
persistent fever, bruising, bleeding, or paleness
* In medical studies of all TNF-inhibitors, a higher rate of lymphoma (a
type of cancer) was seen compared to the general population, however,
the risk of lymphoma may be up to several fold higher in RA patients.
The role of TNF-inhibitors in the development of lymphoma is unknown.
* The incidence of other cancers has not increased with extended
exposure to ENBREL and is similar to the expected rate.
* ENBREL can also cause injection site reactions.
* In a medical study of patients with JRA, infections, headaches,
abdominal pain, vomiting, and nausea occurred more frequently than in
- The kinds of infections reported were generally mild and similar to
those usually seen in children
- Other serious adverse reactions were reported rarely, including
serious infections (2 percent) and depression/personality disorder
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, market ENBREL in
North America. Wyeth markets ENBREL outside of North America. Immunex
Corporation, a wholly owned subsidiary of Amgen, manufactures ENBREL.
Additional information about ENBREL, including full Prescribing Information,
can be found on the Web site sponsored by the companies at www.enbrel.com or
by calling toll free 888-4ENBREL (888-436-2735).
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on advances in
cellular and molecular biology.
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the
areas of women's health care, cardiovascular disease, central nervous system,
inflammation, hemophilia, oncology and vaccines. Wyeth is one of the world's
largest research-driven pharmaceutical and health care products companies. It
is a leader in the discovery, development, manufacturing, and marketing of
pharmaceuticals, vaccines, biotechnology products and non-prescription
medicines that improve the quality of life for people worldwide. The
Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer
Healthcare and Fort Dodge Animal Health.
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below and
others that can be found in Amgen's Form 10-K for the year ended December 31,
2002, and in Amgen's periodic reports on Form 10-Q and Form 8-K. Amgen is
providing this information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements contained in
this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may
differ materially from those we project. Amgen's results may be affected by
its ability to successfully market both new and existing products domestically
and internationally, sales growth of recently launched products, difficulties
or delays in manufacturing its products, and regulatory developments (domestic
or foreign) involving current and future products and manufacturing
In addition, sales of Amgen's products are affected by reimbursement
policies imposed by third party payors, including governments, private
insurance plans and managed care providers, and may be affected by domestic
and international trends toward managed care and healthcare cost containment
as well as possible U.S. legislation affecting pharmaceutical pricing and
reimbursement. Government regulations and reimbursement policies may affect
the development, usage and pricing of Amgen's products. Furthermore, Amgen's
research, testing, pricing, marketing and other operations are subject to
extensive regulation by domestic and foreign government regulatory
authorities. Amgen or others could identify side effects or manufacturing
problems with its products after they are on the market.
In addition, Amgen competes with other companies with respect to some of
its marketed products as well as for the discovery and development of new
products. Discovery or identification of new product candidates cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate will be
successful and become a commercial product.
In addition, while Amgen routinely obtains patents for its products and
technology, the protection offered by its patents and patent applications may
be challenged, invalidated or circumvented by its competitors. Further, some
raw materials, medical devices and component parts for Amgen's products are
supplied by sole third party suppliers.
The statements in this press release that are not historical facts are
forward-looking statements based on current expectations of future events that
involve risks and uncertainties including, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research, product
development, manufacturing, and commercialization, and economic conditions,
including interest and currency exchange rate fluctuations, the impact of
competitive or generic products, product liability and other types of
lawsuits, the impact of legislative and regulatory compliance and obtaining
approvals, and patents, and other risks and uncertainties, including those
detailed from time to time in Wyeth's periodic reports, including quarterly
reports on Form 10-Q and the Annual Report on Form 10-K, filed with the
Securities and Exchange Commission.
Actual results may vary materially from the forward-looking statements.
Wyeth assumes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise.
For further information please contact Media, Andrea Rothschild,
+1-805-447-6287, or cell, +1-818-681-8660, or Investors, Cary Rosansky,
+1-805-447-1060, both of Amgen; or Media, Douglas Petkus, +1-484-865-5140, or
Investors, Justin Victoria, +1-973-660-5340, both of Wyeth Pharmaceuticals.
CONTACT: Media, Andrea Rothschild, +1-805-447-6287, or cell,
+1-818-681-8660, or Investors, Cary Rosansky, +1-805-447-1060, both of Amgen;
or Media, Douglas Petkus, +1-484-865-5140, or Investors, Justin Victoria,
+1-973-660-5340, both of Wyeth Pharmaceuticals
Web site: http://www.enbrel.com
Web site: http://www.amgen.com